SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-096142
Filing Date
2024-08-13
Accepted
2024-08-13 16:03:18
Documents
52
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q inkt-20240630.htm   iXBRL 10-Q 1066416
2 EX-10.1 inkt-ex10_1.htm EX-10.1 342531
3 EX-31.1 inkt-ex31_1.htm EX-31.1 15253
4 EX-31.2 inkt-ex31_2.htm EX-31.2 15217
5 EX-32.1 inkt-ex32_1.htm EX-32.1 10339
  Complete submission text file 0000950170-24-096142.txt   4754228

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT inkt-20240630.xsd EX-101.SCH 740728
54 EXTRACTED XBRL INSTANCE DOCUMENT inkt-20240630_htm.xml XML 501386
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40908 | Film No.: 241201276
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)